Taylor I, Brooman P, Rowling J T
Br Med J. 1977 Nov 19;2(6098):1320-2. doi: 10.1136/bmj.2.6098.1320.
Fifty consecutive patients with colorectal cancer but no evidence of secondary deposits in the liver were included in an ongoing controlled clinical trial of adjuvant liver perfusion aimed at reducing the incidence of hepatic metastases. All patients had their primary tumour resected in the standard way. Twenty-six of the patients served as controls, and 24 received fluorouracil, 1 g daily, as a continuous infusion into the portal venous system during the first seven days after operation. The patients were matched for age, sex, and site and stage of the disease. The immediate postoperative mortality and morbidity did not differ significantly between the two groups. During the follow-up period (mean duration 15.5 months), however, six deaths occurred in the control group and only one in the perfusion group. At necropsy four of the controls had multiple liver metastases. Two of the surviving controls developed evidence of liver metastases, and two had a local recurrence. No patient in the perfusion group developed evidence of hepatic metastases. These initial results suggest that adjuvant portal venous perfusion with fluorouracil may reduce the incidence of liver metastases in colorectal cancer.
五十名连续的结直肠癌患者，且无肝脏继发性转移证据，被纳入一项正在进行的辅助性肝灌注对照临床试验，旨在降低肝转移的发生率。所有患者均以标准方式切除原发性肿瘤。其中二十六名患者作为对照组，二十四名患者在术后头七天内通过门静脉系统持续输注每日1克氟尿嘧啶。患者在年龄、性别、疾病部位和分期方面进行了匹配。两组患者术后即刻死亡率和发病率无显著差异。然而，在随访期间（平均时长15.5个月），对照组有六人死亡，而灌注组仅有一人死亡。尸检时，四名对照组患者有多处肝转移。两名存活的对照组患者出现肝转移迹象，两名有局部复发。灌注组没有患者出现肝转移迹象。这些初步结果表明，氟尿嘧啶辅助门静脉灌注可能降低结直肠癌肝转移的发生率。
